Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

globenewswire.com
ABT Abbott Laboratories is mentioned as a key player in the neurological biomarkers market, indicating their involvement in the Alzheimer's disease biomarker space. The article does not provide specific sentiment towards Abbott's performance or prospects. BIO Bio-Rad Laboratories, Inc. is listed as a key company in the neurological biomarkers and blood-based biomarkers markets, suggesting their participation in the Alzheimer's disease biomarker sector. No specific sentiment is expressed. AMGN Amgen Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Amgen's performance or prospects in the Alzheimer's biomarker space. BMY Bristol Myers Squibb is mentioned as a key company in both the Alzheimer's disease market and the agitation in Alzheimer's disease market. The article does not provide specific sentiment towards the company's performance or prospects. AXSM Axsome Therapeutics, Inc. is listed as a key company in both the Alzheimer's disease market and the agitation in Alzheimer's disease market. The article does not provide specific sentiment towards the company's performance or prospects. JNJ Johnson & Johnson is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Johnson & Johnson's performance or prospects in this area. LLY Eli Lilly and Company is listed as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Eli Lilly's performance or prospects. NVO Novo Nordisk is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Novo Nordisk's performance or prospects. QTRX Quanterix Corporation is mentioned multiple times as a key player in the neurological biomarkers, biomarkers, and blood-based biomarkers markets, indicating its significance in Alzheimer's disease biomarker development. No specific sentiment is expressed. DGX Laboratory Corporation of America Holdings is mentioned as a key company in the biomarkers and blood-based biomarkers markets. The article does not provide specific sentiment towards its performance or prospects in the Alzheimer's biomarker space. TMO Thermo Fisher Scientific Inc. is listed as a key company in the neurological biomarkers and blood-based biomarkers markets. The article does not provide specific sentiment towards its performance or prospects in the Alzheimer's biomarker space. QRVO Qorvo, Inc. is mentioned as a key player in the semiconductor industry, which is indirectly related to the infrastructure for advanced diagnostics. However, the article does not directly link Qorvo to Alzheimer's biomarker development or provide specific sentiment. GILD Gilead Sciences, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Gilead's performance or prospects. REGN Regeneron Pharmaceuticals, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Regeneron's performance or prospects. BIIB Biogen Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Biogen's performance or prospects. ALKS Alkermes plc is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Alkermes' performance or prospects. ACAD Acadia Pharmaceuticals Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Acadia's performance or prospects. PTGX Protagonist Therapeutics, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Protagonist's performance or prospects. CRIS CRISPR Therapeutics AG is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards CRISPR Therapeutics' performance or prospects. EXAS Exact Sciences Corporation is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Exact Sciences' performance or prospects. TDOC Teladoc Health, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Teladoc Health's performance or prospects. QRHC QRxPharma Limited is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards QRxPharma's performance or prospects. AMZN Amazon.com, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Amazon's performance or prospects in this area. GOOG Alphabet Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Alphabet's performance or prospects in this area. MSFT Microsoft Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Microsoft's performance or prospects in this area. IBM International Business Machines Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards IBM's performance or prospects in this area. NVDA NVIDIA Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards NVIDIA's performance or prospects in this area. INTC Intel Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Intel's performance or prospects in this area. AMD Advanced Micro Devices, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards AMD's performance or prospects in this area. QCOM Qualcomm Incorporated is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Qualcomm's performance or prospects in this area. AMAT Applied Materials, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Applied Materials' performance or prospects in this area. LRCX Lam Research Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Lam Research's performance or prospects in this area. KLAC KLA Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards KLA's performance or prospects in this area. MU Micron Technology, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Micron Technology's performance or prospects in this area. ADI Analog Devices, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Analog Devices' performance or prospects in this area. NXPI NXP Semiconductors N.V. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards NXP Semiconductors' performance or prospects in this area. TXN Texas Instruments Incorporated is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Texas Instruments' performance or prospects in this area. MRVL Marvell Technology, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Marvell Technology's performance or prospects in this area. ON ON Semiconductor Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards ON Semiconductor's performance or prospects in this area. CDNS Cadence Design Systems, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Cadence Design Systems' performance or prospects in this area. SNPS Synopsys, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Synopsys' performance or prospects in this area. MCHP Microchip Technology Incorporated is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Microchip Technology's performance or prospects in this area. AEHR Aehr Test Systems is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Aehr Test Systems' performance or prospects in this area. ENPH Enphase Energy, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Enphase Energy's performance or prospects in this area. PLUG Plug Power Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Plug Power's performance or prospects in this area. FCEL FuelCell Energy, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards FuelCell Energy's performance or prospects in this area. PLTR Palantir Technologies Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Palantir Technologies' performance or prospects in this area. AI C3.ai, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards C3.ai's performance or prospects in this area. CRBU Caribou Biosciences, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Caribou Biosciences' performance or prospects. EDIT Editas Medicine, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Editas Medicine's performance or prospects. BEAM Beam Therapeutics Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Beam Therapeutics' performance or prospects. NTLA Intellia Therapeutics, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Intellia Therapeutics' performance or prospects. BNTX BioNTech SE is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards BioNTech's performance or prospects. MRNA Moderna, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Moderna's performance or prospects. PFE Pfizer Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Pfizer's performance or prospects. JAZZ Jazz Pharmaceuticals plc is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Jazz Pharmaceuticals' performance or prospects. ACGL Arch Capital Group Ltd. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Arch Capital Group's performance or prospects. ZBRA Zebra Technologies Corporation is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Zebra Technologies' performance or prospects in this area. MSCI MSCI Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards MSCI's performance or prospects in this area. ROST Ross Stores, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Ross Stores' performance or prospects in this area. SWKS Skyworks Solutions, Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Skyworks Solutions' performance or prospects in this area. MDT Medtronic plc is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Medtronic's performance or prospects. TNDM Tandem Diabetes Care, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Tandem Diabetes Care's performance or prospects. XRAY DENTSPLY SIRONA Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards DENTSPLY SIRONA's performance or prospects. ALGN Align Technology, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Align Technology's performance or prospects. IDXX IDEXX Laboratories, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards IDEXX Laboratories' performance or prospects. EXPE Expedia Group, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Expedia Group's performance or prospects. CTAS Cintas Corporation is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Cintas Corporation's performance or prospects. ILMN Illumina, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Illumina's performance or prospects. DXCM Dexcom, Inc. is mentioned as a key company in the Alzheimer's disease market. The article does not provide specific sentiment towards Dexcom's performance or prospects. ASML ASML Holding N.V. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards ASML Holding's performance or prospects in this area. ADBE Adobe Inc. is mentioned as a key player in the neurological biomarkers market. The article does not provide specific sentiment towards Adobe's performance or prospects in this area.

Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight New York, USA, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight

The Alzheimer’s disease biomarker market is experiencing steady growth, driven by the rising prevalence of Alzheimer’s disease and dementia, increasing emphasis on early and accurate diagnosis, and the growing adoption of biomarker-based approaches in disease management. The market is also benefiting from rapid advancements in blood-based biomarkers, particularly phosphorylated tau (p-tau) and amyloid-beta assays, which offer less invasive and more accessible alternatives to cerebrospinal fluid testing and PET imaging.

DelveInsight’s Alzheimer’s Disease Biomarker Market Insights report provides the current and forecast market analysis, individual leading Alzheimer’s disease biomarker companies’ market shares, challenges, Alzheimer’s disease biomarker market drivers, barriers, trends, and key Alzheimer’s disease biomarker companies in the market.

Alzheimer’s Disease Biomarker Market Summary

To read more about the latest highlights related to the Alzheimer’s disease biomarker news, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/alzheimers-disease-biomarker-market

Key Factors Contributing to the Rise in Growth of the Alzheimer’s Disease Biomarker Market

Get a sneak peek at the Alzheimer’s disease biomarker market dynamics @ Alzheimer’s Disease Biomarker Market Trends

Regional Alzheimer’s Disease Biomarker Market Insights

North America

Europe

Asia-Pacific

To know more about why North America is leading the market growth in the Alzheimer’s disease biomarker market, get a snapshot of the Alzheimer’s Disease Biomarker Market Share

Recent Developmental Activities in the Alzheimer’s Disease Biomarker Market

What is Alzheimer’s Disease Biomarker?

Alzheimer’s disease biomarkers are measurable biological indicators that provide information about the underlying pathological processes associated with the disease. These biomarkers can help detect and characterize Alzheimer’s-related changes, support diagnosis and differential diagnosis, monitor disease progression, and assess responses to emerging therapies. Key biomarkers include amyloid-beta (Aβ) plaques, tau pathology, and neurodegeneration or neuronal injury markers. Amyloid-beta biomarkers, such as Aβ42/40 ratios in cerebrospinal fluid (CSF) or plasma, indicate amyloid accumulation, while phosphorylated tau (p-tau), including p-tau181 and p-tau217, reflects tau pathology and has emerged as an important indicator of Alzheimer’s disease. Other biomarkers, such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), provide information on neuronal injury and neuroinflammation. Advances in blood-based biomarker testing are increasingly improving the accessibility of Alzheimer’s disease detection and monitoring, potentially enabling earlier identification of individuals at risk and supporting more efficient clinical development of disease-modifying therapies.

Alzheimer’s Disease Biomarker Market Assessment

Which MedTech key players in the Alzheimer’s disease biomarker market are set to emerge as the trendsetter explore @ Alzheimer’s Disease Biomarker Market Analysis

Table of Contents

Interested in knowing the Alzheimer’s disease biomarker market share by 2034? Click to get a snapshot of the Top Alzheimer’s Disease Biomarkers

Related Reports

Neurological Biomarkers Market

Neurological Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key neurological biomarkers companies such as Abbott, Merck KGaA, Quanterix, Bio-Rad Laboratories, Inc., Banyan Biomarkers, Inc., Quanterix, Thermo Fisher Scientific, Fujirebio, Bio-Techne, ADx NeuroSciences NV, F. Hoffmann-La Roche Ltd., BIOMÉRIEUX, Siemens Healthineers, Quibim, C₂N Diagnostics, and others.

Biomarkers Market

Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biomarkers companies such as F. Hoffmann-La Roche Ltd, Merck KGaA, Quibim, Quanterix, Abbott, QIAGEN, Revvity, Laboratory Corporation of America® Holdings, Charles River Laboratories., Bio-Rad Laboratories, Inc., Eurofins Scientific, BIOMÉRIEUX, Agilent Technologies, Inc., JSR Life Sciences, LLC, MESO SCALE DIAGNOSTICS, LLC., EKF Diagnostics, Celerion, Standard BioTools™, R-Biopharm AG, StressMarq Biosciences Inc., and others.

Blood-Based Biomarkers Market

Blood-Based Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key blood-based biomarkers companies such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Quanterix Corporation, Fujirebio Holdings, Inc., Guardant Health, Inc., and others.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, and others.

Agitation in Alzheimer’s Disease Market

Agitation in Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key agitation in Alzheimer’s disease companies, including IGC Pharma, Suven Life Sciences, Exciva GmbH, Bristol Myers Squibb, Karuna Therapeutics, Otsuka Pharmaceutical, Lundbeck, Axsome Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.